Clinfo.ai: An Open Source Tool for Answering Medical Questions Based on Scientific Literature

Baichuan Intelligent's Wang Xiaochuan: Focusing on Baixiao Ying, AI Medicine, and other areas

Today, on the second anniversary of Baichuan Intelligent's founding, the company's founder and CEO Wang Xiaochuan released an all-staff letter, reviewing the past two years' achievements and shortcomings, and clarifying the company's current and future development direction. Wang Xiaochuan emphasized that Baichuan Intelligent will firmly pursue its technological vision and business direction in the medical field, promoting the deep application of AI technology in the medical industry through the path of "creating doctors - changing paths - promoting medicine".

AI Detects Early Pancreatic Cancer in 65-Year-Old Patient with Dizziness

A medical team at Ningbo University Affiliated People's Hospital recently used artificial intelligence to successfully detect early-stage pancreatic cancer in a seemingly routine case. 65-year-old Mr. Qiu visited the hospital due to dizziness for three consecutive days. While routine examinations revealed no abnormalities, the AI system, through in-depth analysis of his imaging data, issued a timely alert indicating a potential risk of pancreatic cancer. This case utilized a "Plain CT Scan + AI" approach, a cutting-edge technology that...

Technology Empowering Life! China's First Birth Health Management Large Model CHANGE Released

Insilico Medicine Secures $110 Million in Series E Funding to Advance AI Platform

Insilico Medicine, a biopharmaceutical company focused on generative artificial intelligence, today announced the successful completion of a $110 million Series E financing round. The round was led by a private equity fund under Value Partners Group (HKG:0806), Pudong New Area Investment, Shanghai Pudong Development Bank Group, Xicheng Capital, and Yixing Guokong. Several new investors focused on the industry and technology sectors also participated, alongside continued support from existing investors.

Insilico Medicine Secures $110 Million in Series E Funding to Advance AI Drug Discovery and Robotics Lab Innovations

Insilico Medicine recently announced the closing of a $110 million Series E financing round, led by Value Partners, a Hong Kong-based firm, with participation from existing and new investors. The funds will be used to refine the company's AI models and support pivotal clinical trials for its lead candidate drug in idiopathic pulmonary fibrosis. The company's small molecule inhibitor, ISM001-055, was recently officially named rentosertib by the U.S. Adopted Names Council, marking a significant milestone for this AI-generated drug candidate.

German Research Team Releases Open-Source GNN Model FIORA to Enhance Mass Spectrometry Analysis Accuracy and Advance Precision Medicine

A German research team has developed and released FIORA, an open-source graph neural network (GNN) model designed to improve the accuracy of mass spectrometry analysis. This advancement is expected to significantly contribute to the progress of precision medicine.

Baichuan Intelligent Adjusts B2B Business, Lays Off Finance Team to Focus on AI Medical

Hunan Province Bans AI-Generated Prescriptions in Online Hospitals

Hunan's medical security bureau recently issued a notice prohibiting the use of artificial intelligence to automatically generate prescriptions in online hospitals. This regulation has drawn significant attention, particularly given the increasing prevalence of internet-based healthcare services. The notice mandates that prescriptions must be issued by licensed physicians who have personally interacted with the patient or their family, ensuring compliance with existing regulations.

First Rare Disease AI Model Deployed in a Chinese Hospital

A significant advancement in Chinese medicine has been achieved with the recent clinical deployment of "Xiehe-Taichu," a rare disease AI model jointly developed by Peking Union Medical College Hospital and the Institute of Automation, Chinese Academy of Sciences. This marks a breakthrough in China's rare disease diagnostic technology and provides a new tool for improving clinical efficiency. The development of this AI model benefits from years of accumulated knowledge on rare diseases in China and the support of genetic testing data from the Chinese population. As the world's first rare disease model tailored to the characteristics of the Chinese population, it...

A University in Shandong Requires Integration with DeepSeek

The Qichacha APP shows that on February 10, Shandong University of Traditional Chinese Medicine released a correction announcement for the smart course construction project (3008), stating that for packages 1, 2, and 3, the project requirements and technical specifications have added "Integration Requirement Importance: General; Technical Specifications: Ability to integrate with DeepSeek model." The budget for package 1 is 2 million yuan, for package 2 is 800,000 yuan, and for package 3 is 1.4 million yuan.